Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teduglutide - Takeda

Drug Profile

Teduglutide - Takeda

Alternative Names: ALX-0600; Gattex; Revestive

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Suspended Crohn's disease
  • No development reported Mucositis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 13 Nov 2018 Shire expects approval of the sNDA for Short bowel syndrome (In infants, In children, In adolescents) in USA by March 2019
  • 13 Nov 2018 The US FDA accepts sNDA for teduglutide for Short bowel syndrome for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top